Hytrin

Terazosin, the active ingredient in Hytrin, is a alpha-1 adrenergic receptor antagonist presented as a tablet for oral use. It treats hypertension and benign prostatic hyperplasia in adult patients. GNH USA supplies Hytrin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Terazosin is used to manage conditions that involve vascular tone and smooth‑muscle tone in the prostate. Hypertension: lowers systemic blood pressure by relaxing arterial smooth muscle. Benign prostatic hyperplasia: improves urinary flow by relaxing prostate and bladder neck smooth muscle.

Terazosin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache. - Fatigue or general weakness. - Nasal congestion or runny nose. - Peripheral edema. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Marked hypotension or syncope. - Priapism (prolonged erection). - Severe allergic reactions such as rash, itching, or swelling. - Liver function abnormalities. - Worsening heart failure. - Rapid or irregular heartbeat.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Renal and hepatic function: assess before starting and adjust if impairment is present. - Orthostatic changes: advise patients to rise slowly to reduce dizziness. - Concomitant antihypertensives: review for additive blood‑pressure‑lowering effects. - History of orthostatic hypotension: use with caution. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Terazosin can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other alpha‑blockers (e.g., prazosin, doxazosin) – risk of profound hypotension. - Potent CYP3A4 inhibitors (e.g., ketoconazole) – increased terazosin plasma levels. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil) – additive vasodilatory effect. - Lithium – possible increase in lithium concentrations. - Strong antihypertensive combinations – may cause excessive blood‑pressure drop.

Moderate Interactions (Monitor Closely): - Diuretics – may enhance orthostatic hypotension. - NSAIDs – can blunt antihypertensive response. - Tricyclic antidepressants – may increase risk of dizziness. - Beta‑blockers – additive heart‑rate lowering effect. - Calcium channel blockers – monitor for combined blood‑pressure effects.